arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Vir Biotechnology, Inc.

VIR
$8.82 ▲ +0.05 (+0.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Vir Biotechnology, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.3B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -16.3%
FCF / Share $-0.90
Trailing P/E
Price / Book 1.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$-29.00K
↓ -100.0%
Net Income Profit after all expenses
$-125.69M
↓ -3.9%
Operating Margin Operating profit as % of sales
-74.8%
↑ +47.3%
FCF / Share Free cash flow per share
$-0.90
↓ -55.3%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters